Roth Capital Maintains Neutral on Seelos Therapeutics, Lowers Price Target to $2.5
Roth Capital analyst Jonathan Aschoff maintains Seelos Therapeutics (NASDAQ:SEEL) with a Neutral and lowers the price target from $4 to $2.5.
Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies
This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Psilocybin Alpha.
In just a couple of years, psychedelics took the world of investing by storm.
Field Trip Health Heads To The Nasdaq As Wall Street Opens Up To “Psychedelics Renaissance”
Excitement around psychedelics grows as major U.S. exchanges make room for more companies in the sector.
The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 6)
Why Seelos Therapeutics Is Moving Today
Seelos Therapeutics, Inc. (NASDAQ: SEEL) shares are trading higher after Guggenheim analyst Yatin Suneja initiated coverage on the stock with a Buy rating and announced an $8 price target.
Guggenheim Initiates Coverage On Seelos Therapeutics with Buy Rating, Announces Price Target of $8
Guggenheim analyst Yatin Suneja initiates coverage on Seelos Therapeutics (NASDAQ:SEEL) with a Buy rating and announces Price Target of $8.